This is a preprint.
Expanding Automated Multiconformer Ligand Modeling to Macrocycles and Fragments
- PMID: 39386683
- PMCID: PMC11463535
- DOI: 10.1101/2024.09.20.613996
Expanding Automated Multiconformer Ligand Modeling to Macrocycles and Fragments
Update in
-
Expanding automated multiconformer ligand modeling to macrocycles and fragments.Elife. 2025 Jun 30;14:RP103797. doi: 10.7554/eLife.103797. Elife. 2025. PMID: 40586518 Free PMC article.
Abstract
Small molecule ligands exhibit a diverse range of conformations in solution. Upon binding to a target protein, this conformational diversity is reduced. However, ligands can retain some degree of conformational flexibility even when bound to a receptor. In the Protein Data Bank (PDB), a small number of ligands have been modeled with distinct alternative conformations that are supported by macromolecular X-ray crystallography density maps. However, the vast majority of structural models are fit to a single ligand conformation, potentially ignoring the underlying conformational heterogeneity present in the sample. We previously developed qFit-ligand to sample diverse ligand conformations and to select a parsimonious ensemble consistent with the density. While this approach indicated that many ligands populate alternative conformations, limitations in our sampling procedures often resulted in non-physical conformations and could not model complex ligands like macrocycles. Here, we introduce several improvements to qFit-ligand, including integrating RDKit for stochastic conformational sampling. This new sampling method greatly enriches low energy conformations of small molecules and macrocycles. We further extended qFit-ligand to identify alternative conformations in PanDDA-modified density maps from high throughput X-ray fragment screening experiments, as well as single-particle cryo-electron microscopy (cryo-EM) density maps. The new version of qFit-ligand improves fit to electron density and reduces torsional strain relative to deposited single conformer models and our prior version of qFit-ligand. These advances enhance the analysis of residual conformational heterogeneity present in ligand-bound structures, which can provide important insights for the rational design of therapeutic agents.
Conflict of interest statement
Conflicts of Interest J.S.F. is a consultant to, shareholder of, and receives sponsored research support from Relay Therapeutics and a consultant to and shareholder of Vilya Therapeutics. H.v.d.B. is an employee of Atomwise Inc, but the work in this publication does not overlap with his role there. A.R.R. is a co-founder of TheRas, Elgia Therapeutics, and Tatara Therapeutics, and receives sponsored research support from Merck, Sharp and Dohme.
Figures







